The economics of outsourcing highly potent molecules has always required careful decisionmaking, but even more so with today’s pipeline that includes less “blockbuster” type drugs and more “niche” or targeted molecules.
New approaches to production decisions are needed in order to balance revenue from smaller patient populations with the cost of complex manufacturing processes that must adhere to stringent safety and regulatory requirements.
This complimentary webinar from Baxter BioPharma Solutions provides insight on:
- The market and the economic risks
- Infrastructure needed
- Compliance and experience – where is your company on the learning curve?